• 1
    Soriano V, Barreiro P, Nunez M. Management of chronic hepatitis B and C in HIV-coinfected patients. J Antimicrob Chemother 2006; 57: 815818.
  • 2
    Alberti A, Clumeck N, Collins S et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42: 615624.
  • 3
    Petrovic LM. HIV/HCV co-infection: histopathologic findings, natural history, fibrosis, and impact of antiretroviral treatment: a review article. Liver Int 2007; 27: 598606.
  • 4
    Konopnicki D, Mocroft A, De Wit S et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19: 593601.
  • 5
    The D:A:D Study Group. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D Study. Arch Intern Med 2006; 166: 16321641.
  • 6
    Soriano V, Puoti M, Sulkowski M et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21: 10731089.
  • 7
    Nunez M, Soriano V. Management of patients co-infected with hepatitis B virus and HIV. Lancet Infect Dis 2005; 5: 374382.
  • 8
    Lincoln D, Petoumenos K, Dore GJ. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med 2003; 4: 241249.
  • 9
    Sullivan PS, Hanson DL, Teshale EH, Wotring LL, Brooks JT. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy. AIDS 2006; 20: 11711179.
  • 10
    Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA 2002; 288: 199206.
  • 11
    Cooper CL, Breau C, Laroche A, Lee C, Garber G. Clinical outcomes of first antiretroviral regimen in HIV/hepatitis C virus co-infection. HIV Med 2006; 7: 3237.
  • 12
    Santiago-Munoz P, Roberts S, Sheffield J, McElwee B, Wendel GD Jr. Prevalence of hepatitis B and C in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol 2005; 193: 12701273.
  • 13
    Rouet F, Chaix ML, Inwoley A et al. HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Cote d'Ivoire: the ANRS 1236 Study. J Med Virol 2004; 74: 3440.
  • 14
    Simpore J, Savadogo A, Ilboudo D et al. Toxoplasma gondii, HCV, and HBV seroprevalence and co-infection among HIV-positive and -negative pregnant women in Burkina Faso. J Med Virol 2006; 78: 730733.
  • 15
    Hershow RC, O'Driscoll PT, Handelsman E et al. Hepatitis C virus coinfection and HIV load, CD4 cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study. Clin Infect Dis 2005; 40: 859867.
  • 16
    British HIV Association. Guidelines for the Management of HIV Infection in Pregnant Women and the Prevention of Mother-To-Child Transmission of HIV. London: British HIV Association, 2007, (accessed 15 January 2008).
  • 17
    England K, Thorne C, Newell ML. Vertically acquired paediatric coinfection with HIV and hepatitis C virus. Lancet Infect Dis 2006; 6: 8390.
  • 18
    European Collaborative Study. The mother-to-child HIV transmission epidemic in Europe: evolving in the East and established in the West. AIDS 2006; 20: 14191427.
  • 19
    Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38: 963974.
  • 20
    Greub G, Ledergerber B, Battegay M et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356: 18001805.
  • 21
    Rodriguez-Mendez ML, Gonzalez-Quintela A, Aguilera A, Carballo E, Barrio E. Association of HCV and HBV markers in Spanish HIV-seropositive patients in relation to risk practices. Hepatogastroenterology 2003; 50: 20932097.
  • 22
    Rancinan C, Neau D, Saves M et al. Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy? AIDS 2002; 16: 13571362.
  • 23
    Mohsen AH, Murad S, Easterbrook PJ. Prevalence of hepatitis C in an ethnically diverse HIV-1-infected cohort in south London. HIV Med 2005; 6: 206215.
  • 24
    Menendez C, Sanchez-Tapias JM, Kahigwa E et al. Prevalence and mother-to-infant transmission of hepatitis viruses B, C, and E in Southern Tanzania. J Med Virol 1999; 58: 215220.
  • 25
    Apea-Kubi KA, Yamaguchi S, Sakyi B, Ofori-Adjei D. HTLV-1 and other viral sexually transmitted infections in antenatal and gynaecological patients in Ghana. West Afr J Med 2006; 25: 1721.
  • 26
    Thio CL, Seaberg EC, Skolasky R Jr. et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 19211926.
  • 27
    Rockstroh JK, Mocroft A, Soriano V et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192: 9921002.
  • 28
    Mocroft A, Phillips AN, Soriano V et al. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005; 21: 527536.
  • 29
    Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186: 2331.
  • 30
    Martinez E, Blanco JL, Arnaiz JA et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15: 12611268.
  • 31
    Perinatal HIV Guidelines Working Group. Safety and toxicity of individual antiretroviral agents in pregnancy (2 November 2007). Supplement to PHSTF Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States, 2007. (accessed 15 January 2008).
  • 32
    Hitti J, Frenkel LM, Stek AM et al. Maternal toxicity with continuous nevirapine in pregnancy. J Acquir Immune Defic Syndr 2004; 36: 772776.
  • 33
    Lyons F, Hopkins S, Kelleher B et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med 2006; 7: 255260.
  • 34
    Natarajan U, Pym A, McDonald C et al. Safety of nevirapine in pregnancy. HIV Med 2007; 8: 6469.
  • 35
    Jamisse L, Balkus J, Hitti J et al. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens. J Acquir Immune Defic Syndr 2007; 44: 371376.
  • 36
    Joao EC, Calvet GA, Menezes JA et al. Nevirapine toxicity in a cohort of HIV-1-infected pregnant women. Am J Obstet Gynecol 2006; 194: 199202.
  • 37
    Perinatal HIV Guidelines Working Group. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States, 2 November 2007. (accessed 15 January 2008).
  • 38
    Rendina D, Vigorita E, Bonavolta R et al. HCV and GBV-c/HGV infection in HIV positive patients in southern Italy. Eur J Epidemiol 2001; 17: 801807.
  • 39
    Department of Health and Human Sciences Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, 1 December 2007. United States Department of Health and Human Sciences; 2007. (accessed 15 January 2008).
  • 40
    Soriano V, Puoti M, Bonacini M et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS 2005; 19: 22140.
  • 41
    Nunez M, Soriano V. Hepatitis C virus (HCV) genotypes and disease progression in HIV/HCV-coinfected patients. J Infect Dis 2005; 191: 13.
  • 42
    Sabin CA, Telfer P, Phillips AN, Bhagani S, Lee CA. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. J Infect Dis 1997; 175: 164168.
  • 43
    Yoo TW, Donfield S, Lail A, Lynn HS, Daar ES. Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease. J Infect Dis 2005; 191: 410.
  • 44
    European Paediatric HCV Network. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis 2005; 41: 4551.
  • 45
    Ramos B, Nunez M, Toro C et al. Changes in the distribution of hepatitis C virus (HCV) genotypes over time in Spain according to HIV serostatus: implications for HCV therapy in HCV/HIV-coinfected patients. J Infect 2007; 54: 173179.
  • 46
    Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006; 13: 3441.
  • 47
    Di Bisceglie AM. Natural history of hepatitis C: its impact on clinical management. Hepatology 2000; 31: 10141018.
  • 48
    Grebely J, Raffa JD, Lai C et al. Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can J Gastroenterol 2007; 21: 447451.
  • 49
    Thomas DL, Astemborski J, Rai RM et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 450456.
  • 50
    Piasecki BA, Lewis JD, Reddy KR et al. Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology 2004; 40: 892899.
  • 51
    Piroth L, Sene D, Pol S et al. Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY). AIDS 2007; 21: 13231331.
  • 52
    Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 2006; 332: 328336.